Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

BACKGROUND: Previous results from an interim analysis of an open-label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to bortezomib monotherapy in patients with relapsed/refractory multiple myeloma who had previously received...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer
Главные авторы: Orlowski, Robert Z., Nagler, Arnon, Sonneveld, Pieter, Bladé, Joan, Hajek, Roman, Spencer, Andrew, Robak, Tadeusz, Dmoszynska, Anna, Horvath, Noemi, Spicka, Ivan, Sutherland, Heather J., Suvorov, Alexander N., Xiu, Liang, Cakana, Andrew, Parekh, Trilok, San-Miguel, Jesús F.
Формат: Artigo
Язык:Inglês
Опубликовано: 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5701574/
https://ncbi.nlm.nih.gov/pubmed/27191689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30026
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы